@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP1325771.RAunE8sZHZ-XZkE0lBE6w8k41UYAEouREISo4NRJKu2DU130_head { this: np:hasAssertion dgn-np:NP1325771.RAunE8sZHZ-XZkE0lBE6w8k41UYAEouREISo4NRJKu2DU130_assertion; np:hasProvenance dgn-np:NP1325771.RAunE8sZHZ-XZkE0lBE6w8k41UYAEouREISo4NRJKu2DU130_provenance; np:hasPublicationInfo dgn-np:NP1325771.RAunE8sZHZ-XZkE0lBE6w8k41UYAEouREISo4NRJKu2DU130_publicationInfo; a np:Nanopublication . dgn-np:NP1325771.RAunE8sZHZ-XZkE0lBE6w8k41UYAEouREISo4NRJKu2DU130_assertion a np:Assertion . dgn-np:NP1325771.RAunE8sZHZ-XZkE0lBE6w8k41UYAEouREISo4NRJKu2DU130_provenance a np:Provenance . dgn-np:NP1325771.RAunE8sZHZ-XZkE0lBE6w8k41UYAEouREISo4NRJKu2DU130_publicationInfo a np:PublicationInfo . } dgn-np:NP1325771.RAunE8sZHZ-XZkE0lBE6w8k41UYAEouREISo4NRJKu2DU130_assertion { miriam-gene:2064 a ncit:C16612 . lld:C0686619 a ncit:C7057 . dgn-gda:DGN48774565d206783421c03ea254ebf21a sio:SIO_000628 miriam-gene:2064, lld:C0686619; a sio:SIO_001121 . } dgn-np:NP1325771.RAunE8sZHZ-XZkE0lBE6w8k41UYAEouREISo4NRJKu2DU130_provenance { dgn-np:NP1325771.RAunE8sZHZ-XZkE0lBE6w8k41UYAEouREISo4NRJKu2DU130_assertion dcterms:description "[This group was compared with the remaining 3,969 patients (FH(-) group) with the following results: (1) The tumor diameter in the FH(+) group was slightly less than that in the FH(-) group [not significant (NS)], with fewer lymph node metastases (P < 0.05); (2) the positive rates for the estrogen receptor were 52% (138/266) and 49% (1,216/2,481), respectively (NS); (3) expression of the c-erbB-2 protein was observed in 14 out of 40 (35%) and 32 out of 100 cases (32%), respectively (NS); (4) the relative risk of bilateral occurrence in the FH(+) group was 1.4, with a 95% confidence interval of 0.9-2.4; (5) the 15-year survival rate was 72% and 60%, respectively, suggesting a better prognosis for the FH(+) group (P < 0.01); and (6) multivariate analysis showed that the contribution of FH to postoperative survival was marginal (P = 0.07).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:7905302; prov:wasDerivedFrom dgn-void:befree-2016; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-2016 pav:importedOn "2016-02-19"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP1325771.RAunE8sZHZ-XZkE0lBE6w8k41UYAEouREISo4NRJKu2DU130_publicationInfo { this: dcterms:created "2016-05-13T12:51:47+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetv3.0rdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v4.0.0.0" . dgn-void:disgenetv3.0rdf pav:version "v4.0.0" . }